Redwood AI (AIRX.CN) is collaborating with Resilience Biosciences to help develop AI-assisted computational chemistry workflows for small-molecule drug development, the company said over the weekend.
Resilience will use Redwood's AI platform to explore new drug-like molecules more efficiently, to identify "useful" chemical designs, a statement said.
"Small-molecule development requires a careful balance of creativity, scientific rigour, synthetic feasibility, and intellectual property awareness. Our goal is to give research teams better tools to explore chemical possibilities in a structured, secure, and scalable way," said Redwood chief executive Louis Dron.
"This collaboration demonstrates how AI can be applied to practical, IP-aware chemistry workflows that support a more efficient path from early molecular ideas to development-ready opportunities," he added.